IOL Chemicals and Pharmaceuticals Q2 Revenue Rises by 40%

IOL Chemicals and Pharmaceuticals Limited reported Q2 FY27 revenue from operations of ₹795 crore, about 40% higher year-on-year, while EBITDA rose nearly 80% to ₹115 crore and profit after tax increased to about ₹65 crore from ₹30 crore a year earlier.

What did IOL report for Q2 and H1 FY27?

IOL reported broad-based growth in its pharmaceuticals and chemicals businesses during the September-quarter period of FY27. Revenue from operations in Q2 FY27 was ₹795 crore, representing growth of approximately 40% from the corresponding quarter of FY26 and 5% from the preceding quarter.

For the first half of FY27, revenue from operations rose approximately 39% year-on-year to ₹1,551 crore. Management attributed the growth to healthy demand across both business segments and an improved product mix. The company said its operating performance was achieved despite geopolitical uncertainty, global supply-chain disruptions and volatility in raw-material prices.

EBITDA for Q2 FY27 was approximately ₹115 crore, compared with ₹64 crore in Q2 FY26. The nearly 80% year-on-year increase in operating profit was supported by better capacity utilisation, operating efficiencies and product-mix improvements, according to the management discussion.

Profit after tax for the quarter rose to approximately ₹65 crore from ₹30 crore in the year-earlier period, an increase of about 170%. For H1 FY27, profit after tax was approximately ₹130 crore, compared with ₹64 crore in H1 FY26.

How did pharmaceuticals and chemicals contribute to growth?

IOL said its non-ibuprofen pharmaceutical portfolio continued to gain scale in Q2 FY27. Revenue from this portfolio increased by approximately 70% year-on-year and represented 45% of pharmaceutical revenue, compared with 38% in the corresponding quarter of the previous year.

The company described this shift as evidence of the growing contribution of its diversified active pharmaceutical ingredient, or API, portfolio. Ibuprofen remains an important business for IOL, and management said it is seeking to reinforce its position through capacity expansion, backward integration and process efficiencies.

The chemicals business also showed a stronger operating contribution. Its share of overall EBIT increased to approximately 7% in Q2 FY27 from around 1% in Q2 FY26. IOL linked the improvement to better realisations, operating efficiencies and disciplined procurement.

Management said its integrated manufacturing operations and investments in capacity enhancement are intended to support the chemicals business. The call did not provide a separate chemicals revenue figure or a specific timeline for these capacity additions.

Which regulatory milestones did IOL achieve in the quarter?

IOL received a Certificate of Suitability, or CEP, from the European Directorate for the Quality of Medicines and HealthCare for phenofibrate process 2 during the quarter. The approval took the company's total CEP approvals to 22.

The company also received Good Manufacturing Practice certification for its formulation contract development and manufacturing organisation facility. Management said the certification strengthens its regulatory credentials and manufacturing capabilities.

These approvals are relevant to a pharmaceutical manufacturer because regulatory clearances form part of the framework for supplying products to regulated markets. However, IOL did not quantify any revenue contribution from the phenofibrate approval or the formulation facility certification during the earnings call.

What were the main Q2 and H1 FY27 financial figures?

IOL's reported figures show that profitability grew faster than revenue in both the quarter and the first half. H1 FY27 EBITDA rose approximately 70% year-on-year to ₹227 crore, while the EBITDA margin improved to 14.5% from 11.8% in H1 FY26.

The higher margin indicates improved operating profitability over the first six months, based on the figures disclosed by management. The company cited product mix, capacity utilisation, procurement discipline and operational efficiency as key factors behind the performance.

What does the update mean for investors and operations?

The Q2 update points to a larger role for non-ibuprofen APIs in IOL's pharmaceutical business, with the portfolio's contribution rising to 45% of pharmaceutical revenue. This development is important because it changes the mix within the pharmaceuticals segment, while ibuprofen remains a core product.

The increase in the chemicals business contribution to overall EBIT also shows that the segment had a more meaningful role in Q2 FY27 than it did a year earlier. Management connected this improvement with realisations and internal operating measures rather than a single disclosed external event.

No share-price movement, customer impact or revised financial forecast was disclosed in the supplied Q2 and H1 FY27 call material. Investors therefore have reported operating and financial metrics to assess, but no basis in this update for drawing conclusions about immediate market performance.

IOL had previously guided for FY27 revenue growth of 15% to 20% and an EBITDA margin of 14% to 15%. It had also outlined annual capital expenditure of about ₹200 crore to ₹250 crore, with around 60% directed towards expansion and new-product development and the balance towards infrastructure, efficiency and cost reduction.

Conclusion

IOL delivered higher revenue, EBITDA and profit in Q2 FY27, supported by growth in non-ibuprofen pharmaceuticals and an improved chemicals contribution. Revenue rose about 40% year-on-year to ₹795 crore, while H1 EBITDA margin reached 14.5%, above the 11.8% reported in the prior-year first half.

The next points to watch are progress against IOL's FY27 guidance of 15% to 20% revenue growth and a 14% to 15% EBITDA margin, alongside the execution of its planned annual capital expenditure of about ₹200 crore to ₹250 crore. Investors can also track whether non-ibuprofen APIs continue moving towards the company's stated longer-term portfolio objective.